
    
      The maximum duration of the study may be up to 523 weeks:

        -  Up to 1-week of screening, if any

        -  At least 264 weeks of open label treatment phase and up to 516 weeks as maximum

        -  6-week post-treatment follow-up as required per protocol.
    
  